Top | Investors | Kyowa Kirin Co., Ltd.

Sorry, you need to enable JavaScript to visit this website.

Stock Chart

株主・投資家の皆様

株価チャート

ピックアップ

パイプライン

パイプライン

私たちが開発中の新薬候補をご紹介します

関連リンク

KIRIN キリンホールディングス

キリンホールディングス

Financial Summary

January 1, 2024 - December 31, 2024

Fiscal Year

2024 Fiscal Year

Consolidated Financial Summary (IFRS) Fiscal 2024 （775KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2024 （1,285KB）
Results Presentation Fiscal 2024 （2,001KB）
Transcript of Results Briefing Fiscal 2024 （4,107KB）
Revenues from other products （22KB）

Third Quarter

Consolidated Financial Summary (IFRS) Fiscal 2024 Third Quarter （687KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2024 Third Quarter （1,261KB）
Results Presentation Fiscal 2024 Third Quarter （1,803KB）
Transcript of Results Briefing Fiscal 2024 Third Quarter （1,751KB）

Second Quarter

Consolidated Financial Summary (IFRS) Fiscal 2024 Second Quarter （667KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2024 Second Quarter （995KB）
Results Presentation Fiscal 2024 Second Quarter （1,805KB）
Transcript of Results Briefing Fiscal 2024 Second Quarter （2,175KB）
Revenues from other products （12KB）

First Quarter

Consolidated Financial Summary (IFRS) Fiscal 2024 First Quarter （574KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2024 First Quarter （1,259KB）
Results Presentation Fiscal 2024 First Quarter （883KB）
Transcript of Results Briefing Fiscal 2024 First Quarter （1,535KB）

January 1, 2023 - December 31, 2023

Fiscal Year

Consolidated Financial Summary (IFRS) Fiscal 2023 （846KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 （1,189KB）
Results Presentation Fiscal 2023 （1,720KB）
Transcript of Results Briefing Fiscal 2023 （3,858KB）
Revenues from other products （12KB）
Annual Securities Report （1,909KB）

Third Quarter

Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter （674KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter （1,125KB）
(Correction) Appendix to the Consolidated Financial Summary Fiscal 2023 Third Quarter （304KB）
Results Presentation Fiscal 2023 Third Quarter （1,071KB）
Transcript of Results Presentation Fiscal 2023 Third Quarter (text) （2,293KB）

Second Quarter

Consolidated Financial Summary (IFRS) Fiscal 2023 Second Quarter （702KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 Second Quarter （930KB）
(Correction) Appendix to the Consolidated Financial Summary Fiscal 2023 Second Quarter （130KB）
Results Presentation Fiscal 2023 Second Quarter （1,183KB）
Transcript of Results Briefing Fiscal 2023 Second Quarter （2,085KB）
Revenues from other products （28KB）

First Quarter

Consolidated Financial Summary (IFRS) Fiscal 2023 First Quarter （655KB）
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 First Quarter （1,729KB）
Results Presentation Fiscal 2023 First Quarter （1,175KB）
Transcript of Results Briefing Fiscal 2023 First Quarter （1,673KB）

January 1, 2022 - December 31, 2022

Fiscal Year

Consolidated Financial Summary (IFRS) Fiscal 2022 （818KB）
Appendix to the Consolidated Financial Summary Fiscal 2022 （1,443KB）
Results Presentation Fiscal 2022 （1,118KB）
Transcript of Results Briefing Fiscal 2022 （2,974KB）
Revenues from other products （27KB）
Annual Securities Report （1,814KB）

Third Quarter

Consolidated Financial Summary Fiscal 2022 Third Quarter （780KB）
Appendix to the Consolidated Financial Summary Fiscal 2022 Third Quarter （1,494KB）
Results Presentation Fiscal 2022 Third Quarter （949KB）
Transcript of Results Briefing Fiscal 2022 Third Quarter (text) （1,945KB）

Second Quarter

Consolidated Financial Summary Fiscal 2022 Second Quarter （770KB）
Appendix to the Consolidated Financial Summary Fiscal 2022 Second Quarter （1,446KB）
Results Presentation Fiscal 2022 Second Quarter （770KB）
Transcript of Results Briefing Fiscal 2022 Second Quarter (text) （2,699KB）

First Quarter

Consolidated Financial Summary Fiscal 2022 First Quarter （734KB）
Appendix to the Consolidated Financial Summary Fiscal 2022 First Quarter （833KB）
Results Presentation Fiscal 2022 First Quarter （708KB）
Transcript of Results Briefing Fiscal 2022 First Quarter (text) （2,879KB）

January 1, 2021 - December 31, 2021

Fiscal Year

Consolidated Financial Summary Fiscal 2021 （841KB）
Appendix to the Consolidated Financial Summary Fiscal 2021 （856KB）
Results Presentation Fiscal 2021 （603KB）
Revenues from other products （25KB）
Transcript of Results Briefing Fiscal 2021 （3,453KB）

Third Quarter

Consolidated Financial Summary Fiscal 2021 Third Quarter （741KB）
Appendix to the Consolidated Financial Summary Fiscal 2021 Third Quarter （868KB）
Results Presentation Fiscal 2021 Third Quarter （515KB）
Transcript of Results Briefing Fiscal 2021 Third Quarter (text) （1,545KB）

Second Quarter

Consolidated Financial Summary Fiscal 2021 Second Quarter （720KB）
Appendix to the Consolidated Financial Summary Fiscal 2021 Second Quarter （889KB）
Results Presentation Fiscal 2021 Second Quarter （566KB）
Revenues from other products （25KB）
Transcript of Results Briefing Fiscal 2021 Second Quarter (text) （1,500KB）

First Quarter

Consolidated Financial Summary Fiscal 2021 First Quarter （592KB）
Appendix to the Consolidated Financial Summary Fiscal 2021 First Quarter （810KB）
Results Presentation Fiscal 2021 First Quarter （565KB）
Transcript of Results Briefing Fiscal 2021 First Quarter (text) （1,070KB）

January 1, 2020 - December 31, 2020

Fiscal Year

Consolidated Financial Summary Fiscal 2020 （601KB）
Appendix to the Consolidated Financial Summary Fiscal 2020 （345KB）
Results Presentation Fiscal 2020 （448KB）
Summary of late-stage clinical trials （566KB）
Revenues from other products （25KB）
Transcript of FY 2020 Results/2021-2025 Medium Term Business Plan Briefing (text) （2,712KB）

Link to 2021-2025 Medium Term Business Plan

Third Quarter

Consolidated Financial Summary Fiscal 2020 Third Quarter （2,152KB）
Appendix to the Consolidated Financial Summary Fiscal 2020 Third Quarter （605KB）
Results Presentation Fiscal 2020 Third Quarter （720KB）
Transcript of Results Briefing Fiscal 2020 Third Quarter (text) （1,102KB）

Second Quarter

Consolidated Financial Summary Fiscal 2020 Interim （2,121KB）
Appendix to the Consolidated Financial Summary Fiscal 2020 Interim （573KB）
Results Presentation Fiscal 2020 Interim （735KB）
Summary of clinical trials （627KB）
Revenues from other products （22KB）
Transcript of Results Presentation Fiscal 2020 Interim (text) （1,274KB）

First Quarter

Consolidated Financial Summary Fiscal 2020 First Quarter （833KB）
Appendix to the Consolidated Financial Summary Fiscal 2020 First Quarter （580KB）
Results Presentation Fiscal 2020 First Quarter （732KB）
Transcript of Results Presentation Fiscal 2020 First Quarter (text) （769KB）

January 1, 2019 - December 31, 2019

Fiscal Year

Consolidated Financial Summary Fiscal 2019 （452KB）
Appendix to the Consolidated Financial Summary Fiscal 2019 （765KB）
Results Presentation Fiscal 2019 （1,045KB）
Summary of late-stage clinical trials （187KB）
Revenues from other products （23KB）
Transcript of Results Presentation Fiscal 2019 (text) （1,499KB）

Third Quarter

Consolidated Financial Summary Fiscal 2019 Third Quarter （536KB）
Appendix to the Consolidated Financial Summary Fiscal 2019 Third Quarter （777KB）
Results Presentation Fiscal 2019 Third Quarter （1,243KB）
Transcript of Results Presentation Fiscal 2019 Third Quarter (text) （697KB）

Second Quarter

Consolidated Financial Summary Fiscal 2019 Interim （251KB）
Appendix to the Consolidated Financial Summary Fiscal 2019 Interim （490KB）
Results Presentation Fiscal 2019 Interim （740KB）
Summary of late-stage clinical trials （227KB）
Revenues from other products （23KB）
Transcript of Results Presentation Fiscal 2019 Interim (text) （1,035KB）

First Quarter

Consolidated Financial Summary Fiscal 2019 First Quarter （204KB）
Appendix to the Consolidated Financial Summary Fiscal 2019 First Quarter （419KB）
Results Presentation Fiscal 2019 First Quarter （569KB）
Transcript of Results Presentation Fiscal 2019 First Quarter (text) （1,507KB）

more

IR Events

Kyowa Kirin rocatinlimab Update

March 10, 2025

Online Meeting Presentation （1,134KB）
Transcript (Text) （2,472KB）

This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.

Kyowa Kirin Sustainability Meeting

November 26, 2024

Online Meeting Presentation （5,565KB）
Transcript (Text) （3,924KB）

Agreement for Global Strategic Collaboration with Kura Oncology to Develop and Commercialize Ziftomenib

November 21, 2024

Online Meeting Presentation （666KB）
Transcript (Text) （1,186KB）

Kyowa Kirin R&D Meeting

September 26, 2024

Online Meeting Presentation （3,155KB）
Transcript (Text) （4,034KB）

Orchard Therapeutics IR Meeting

April 8, 2024

Online Meeting Presentation （1,979KB）
Transcript (Text) （2,731KB）

Kyowa Kirin R&D Meeting

December 11, 2023

Online Meeting Presentation （3,058KB）
Transcript (Text) （4,515KB）

Agreement to acquire shares of Orchard Therapeutics

October 5, 2023

Kyowa Kirin ESG Meeting

October 3, 2023

ESG Meeting Presentation （3,786KB）
Transcript (Text) （3,145KB）

Kyowa Kirin R&D Meeting

December 5, 2022

R&D Meeting Presentation （1,896KB）
Transcript (Text) （3,368KB）

Kyowa Kirin ESG Meeting

October 12, 2022

ESG Meeting Presentation （11,701KB）
Transcript (text) （12,267KB）

40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

The webcast will be available until January 13, 2023.

Update on KHK4083

October 4, 2021 (Material added on November 5, 2021)

Pathogenesis and Latest Therapy of Atopic Dermatitis （673KB）
EADV Follow-up （456KB）
ISDS Presentation (Nov. 5 added) （482KB）
Transcript (text) （3,492KB）

Kyowa Kirin ESG Briefing

September 8, 2021

ESG Briefing Presentation （6,515KB）
Transcript (text) （6,250KB）

Joint Development and Commercial Agreement of KHK4083 with Amgen

June 1, 2021

Presentation （333KB）
Transcript (text) （951KB）
News Release

R&D Day

December 10, 2020

R&D Day Presentation （1,406KB）
Transcript (text) （2,871KB）

Updates on Nourianz marketing strategy in the U.S. and KW-6356 development

November 19, 2019

Agenda （101KB）
2019 US NOURIANZ Commercial Update （2,170KB）
A Phase 2a Study of KW-6356 in the Subjects with Parkinson's Disease （1,398KB）
Transcript (text) （2,086KB）

Update on KHK4083: A phase 1 study in subjects with atopic dermatitis

December 3, 2018

Agenda （78KB）
A phase 1 study of KHK4083 in subjects with atopic dermatitis （1,043KB）

Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU

October 27, 2017

Agenda （388KB）
Clinical/Regulatory Updates of Burosumab and The Current Pre-launch Activities in EU （827KB）

more

IR News

March 31, 2025 Matters Concerning Controlling Shareholders （129KB）
March 19, 2025 Corporate Governance Report （933KB）
March 19, 2025 Notice Regarding Disposal of Treasury Shares Used for Restricted Share-Based Remuneration and Performance-Linked Share-Based Remuneration （206KB）
March 08, 2025 AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS （435KB）
February 06, 2025 Appendix to the Consolidated Financial Summary Fiscal 2024 （1,285KB）

全てのニュース

more

IR Contents

Management

Financial Data

Reports & Presentations

Investor Calendar

Stock & Rating

Integrated Report

ESG Data

CSV Materiality and SDGs

GRI Standard Index

Directors & Officers

FTSE Blossom Japan Sector Relative Index

2021 Sompo Sustainability index

2021 constituent MSCI Japan ESG select leaders index

2021 constituent MSCI Japan Empowering Women index

Morningstar Japan ex-REIT Gender Diversity Tilt Index

Integrated Report

ESG Data

CSV Materiality and SDGs

GRI Standard Index

Directors & Officers

This website is intended for the use of shareholders and investors.
The "Investors" contents are created and published to provide information on the Company's activities to shareholders and investors and not offer information to the general public.

Are you a shareholder or an investor?

Yes